Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO John Maraganore sold 74,000 shares of the stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $126.86, for a total value of $9,387,640.00. Following the transaction, the chief executive officer now owns 223,710 shares in the company, valued at $28,379,850.60. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.
John Maraganore also recently made the following trade(s):
- On Wednesday, November 22nd, John Maraganore sold 73,415 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $130.90, for a total value of $9,610,023.50.
Alnylam Pharmaceuticals, Inc. (ALNY) traded down $9.30 during trading on Monday, hitting $128.01. The company’s stock had a trading volume of 1,306,260 shares, compared to its average volume of 1,150,462. The company has a debt-to-equity ratio of 0.14, a current ratio of 9.83 and a quick ratio of 9.83. Alnylam Pharmaceuticals, Inc. has a twelve month low of $35.98 and a twelve month high of $147.63.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The firm had revenue of $17.10 million during the quarter, compared to the consensus estimate of $28.15 million. During the same period in the previous year, the firm earned ($1.21) EPS. The business’s revenue was up 24.8% on a year-over-year basis. equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -5.21 earnings per share for the current year.
Several institutional investors and hedge funds have recently modified their holdings of ALNY. QS Investors LLC grew its holdings in Alnylam Pharmaceuticals by 59.7% during the second quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock valued at $192,000 after purchasing an additional 900 shares during the period. The Manufacturers Life Insurance Company lifted its position in shares of Alnylam Pharmaceuticals by 7.0% in the second quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 167 shares in the last quarter. Prudential Financial Inc. purchased a new position in shares of Alnylam Pharmaceuticals in the first quarter valued at about $215,000. CIBC Asset Management Inc purchased a new position in shares of Alnylam Pharmaceuticals in the second quarter valued at about $221,000. Finally, Neuberger Berman Group LLC purchased a new position in shares of Alnylam Pharmaceuticals in the second quarter valued at about $229,000. 88.43% of the stock is owned by institutional investors.
Several equities analysts recently issued reports on ALNY shares. Goldman Sachs Group upgraded Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price target for the stock from $62.00 to $163.00 in a research report on Monday, October 2nd. Jefferies Group set a $102.00 price target on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 25th. B. Riley reduced their price target on Alnylam Pharmaceuticals to $220.00 and set a “buy” rating on the stock in a research report on Wednesday, November 8th. Barclays raised their price target on Alnylam Pharmaceuticals from $50.00 to $70.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 10th. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $99.00 price objective (down previously from $105.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 6th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and seventeen have given a buy rating to the stock. Alnylam Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $121.85.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/04/john-maraganore-sells-74000-shares-of-alnylam-pharmaceuticals-inc-alny-stock.html.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.